We used a capture ELISA to quantify the E7 protein of human papillomavirus type 18 (HPV-18). In HeLa cells, which express low levels of immunoreactive E7 protein (lET), iE7 had a mean half-life of 13-5 min. In HPV-18 E7 recombinant baculovirus (E7rec BV)-infected Sf21 cells, which express higher levels of E7, the half-life of iE7 was much longer (90 rain and > 24 h, with two different E7rec BVs). For two transformed human cervical cell lines expressing HPV-18 E7, exposure of the cells to hydrocortisone resulted in a twofold increase in steady-state levels of the E7 protein: no similar effect was observed with progesterone, oestrogen or testosterone. The half-life of iE7 was unaltered by hydrocortisone or progesterone exposure. An immunoassay which distinguished SerS3-phosphorylated E7 from E7 not phosphorylated at this residue (Ser3Mephospho-E7), showed that in HeLa and Sf21 cells the majority of E7 was phosphorylated: the half-life of both species of E7 was similar in HeLa cells, but the half-life of Ser33dephospho-E7 was much shorter (90 min) in Sf21 cells than that of Ser~3phospho-E7 (> 24 h). A HeLafibroblast fusion cell line with tumorigenic potential (CGL-1) had a similar ratio of dephospho-E7 to total E7 (0-06), as a similar fusion cell line (CGL-4) with no tumorigenic potential (0-03). We conelude that E7 is a labile phosphoprotein, and that the expression and steady-state level of the E7 protein in eukaryotic cells may be influenced by the hormonal environment of the cells.
Introduction
Papillomaviruses are dsDNA viruses that infect skin and mucosal surfaces, causing benign tumours. Human papillomaviruses (HPVs), particularly HPV-16 and -18, have been implicated in the aetiology of cervical and other human cancers. The gene products of two early open reading frames (ORFs), E6 and E7, are together sufficient to immortalize human keratinocytes in vitro (Bedell et al., 1987; Barbosa & Schlegel, 1989; Miinger et al., 1989a) , and expression of the E70RF in conjunction with the activated ras gene is sufficient to transform primary epithelial cells to a malignant phenotype (Crook et al., 1989) . E7 is thought to disturb cell cycle regulation by binding to the retinoblastoma gene product RB and interfering with the interaction of this protein with other cell cycle regulatory proteins (Miinger et al., 1989b) . However, studies on the biological activity of the E7 protein have been hampered by the lack of quantitative assays for E7, which is present only in small amounts in "~ Present address: National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, U.S.A. transformed cells. The steady-state concentration of E7 protein in cells has generally been inferred from mRNA assays or semi-quantitative immunological techniques (Bosch et al., 1990; von Knebel Doeberitz et al., 1991; Smotkin & Wettstein, 1986; Seedorf et al., 1987) . Recently we described a series of monoclonal antibodies (MAbs) specific for the E7 proteins of HPV-16 and -18, and a capture ELISA for the immunoreactive E7 protein (iE7), based on these antibodies (Selvey et al., 1992) . We now confirm with this assay that the E7 protein is labile, and have used the assay to investigate the phosphorylation of E7 in E7-transformed cell lines, and the effect of steroid hormones on the half-life and steady-state level of the E7 protein in the transformed cell.
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Dr David Bishop, Oxford, U.K. and was maintained in TC 100 medium with tryptose broth (CSL Laboratories) supplemented with penicillin, streptomycin, sodium bicarbonate (Flow Laboratories) and 10 % FBS.
The expression plasmid for the MS2 replicase-HPV-18 E7 fusion protein (MS2/E718) was a gift from Dr Lutz Gissmann. Partial purification of the resultant fusion protein, production of a polyclonal antiserum, and of MAbs, has been described previously Selvey et al., 1990) . E7 recombinant baculoviruses were prepared as described (Emery & Bishop, 1987) (Park et al., 1993) .
Immunoprecipitation. HeLa cells at 75% confluence in an 80cm 2 tissue culture flask were labelled for 1.5 h with 500 laCi of L-[35S]cysteine (Amersham) in cysteine-free DMEM (CSL Laboratories), or 1 mCi of a~Pi (Amersham) in phosphate-free RPMI 1640 (CSL Laboratories) after first incubating the cells in phosphate-or cysteine-deficient medium at 37 °C for 1 h as appropriate. All media were supplemented with 10% dialysed FBS. The cells were lysed on ice in cell lysis buffer [250 mM-NaC1, 0.1% NP40 (Sigma), 50 mM-HEPES, 5 % FBS, 1 lag/ml aprotinin pH 7.0 (Boehringer Mannheim) and the immunoprecipitations were carried out as previously described . Preparation of cell lysates. This has been described previously (Selvey et al., 1992) . Briefly, adherent cells were placed on ice, washed twice in ice-cold PBS and then lysed in 0.1% NP40 in PBS containing 1 ~tg/ml aprotinin. Sf21 cells that had been infected 48 h previously with recombinant baculovirus at a high multiplicity were pelleted and lysed by adding the appropriate volume of cell lysis buffer. For cycloheximide treatment, fresh tissue culture medium containing 50 p_g/ml of cycloheximide in ethanol (Sigma), or 0.1% ethanol was added to logphase cells in quadruplicate for 1 to 4 h. Hydrocortisone, progesterone, testosterone, fl-oestradiol and cortexolone (all from Sigma) were dissolved in 100 % ethanol and added to the tissue culture medium of confluent cells at the appropriate concentration 2 days prior to the assay. The maximum ethanol concentration in the cultures was 0" 1%.
ELISAfor E7. This was performed essentially as described (Selvey et al., 1992) . Cell lysates were incubated on a microtitre plate coated with an appropriate MAb, usually 7El0, for 1 to 2 h at 4 °C. Following extensive washing the plates were incubated for 1 h at 37 °C with polyclonal rabbit antiserum against the MS2 replicase-HPV-18 E7 fusion protein, diluted 1:200 in ELISA wash buffer. After further washing, peroxidase-labelled goat anti-rabbit immunoglobulin (Silenius Laboratories), diluted 1 : 1000 in wash buffer, was added and the plates were incubated for 1 h at 37 °C. The colour reaction was obtained by adding 0-2 M-o-phenylenediamine (BDH) and was then assessed by measuring A492. iE7 protein was estimated by comparing the A492 value with that obtained with known concentrations of MS2 replicase-HPV-18 E7 fusion protein. Cell lysates containing the E7 protein of HPV-16 were used as a negative control for the assay. Results were expressed as an estimation of the amount of HPV-18 iE7 per mg of cellular protein. Total cellular protein concentration was estimated by the method of Bradford using the Bio-Rad assay kit. The difference (A) in iE7 between hormone-treated and control cells was calculated as: AE7 = [A49 ~ (treated)-mean A492 (EtOH)]/mean A492 (EtOH). The statistical significance of differences between iE7 in hormone-treated and untreated cells was calculated using Student's ttest. Exponential decay curves to estimate the half-life of the E7 protein were constructed using In-Plot (GraphPAD software).
Alkaline phosphatase treatment of cell lysates. Aliquots (200 lal) of cell lysate were adjusted to pH 9"0 with 10 ~tl 1.5 M-Tris-HC1 pH 9.4. Alkaline phosphatase (Boehringer Mannheim) was added to a final concentration of 100 U/ml and incubated at 37 °C. The reaction was stopped by the addition of 2 lal of 1 M-DTT and the pH was neutralized with 2 M-HC1. Control samples at pH 9-0 were incubated at 37 °C for 10 min without the enzyme after which DTT and HCt were added as indicated above. Following incubation at 37 °C, samples were placed on ice, and E7 was assayed by sandwich ELISA.
Two-dimensional (2D) gel analysis of iE7.
Cells were suspended in 0.5% NP40 in 150 mM-NaC1, 25 mM-Tris-HCl pH 8-0, 1 mM-MgC12 with aprotinin and leupeptin (lysis buffer), passed through a 20-gauge needle and held on ice for 20 min. Lysate was centrifuged at 12 000 g for 10 min, and 1 ml supernatant was adjusted to pH 9.0 with 60 Ixl 1.5 MTris-HC1 pH 10. Where appropriate, 250 U alkaline phosphatase (Boehringer Mannheim) was added and the mixture was held at 37 °C for 15 min. Reaction was stopped with 2 ~tl DTT, and the pH adjusted to 7.5 with 17.5 lal of 2 M-HC1. Lysate was diluted 1 : 1 with lysis buffer, and E7 was immunoprecipitated after the addition of the appropriate MAb for 2 h at 4 °C, using Protein A-Sepharose beads (Pharmacia). Beads were washed five times in wash buffer (0"1% NP40 in 150 mMNaC1, 25 mM-Tris-HCl pH 8"0, 1 mM-MgC12 with aprotinin and leupeptin) and incubated for 30 min at 37 °C in isoelectric focusing (IEF) sample buffer. Samples were subjected to equilibrium IEF, PAGE and electroblotting as previously described (Frazer et al., 1985) .
Blots were blocked with 3 % BSA, 0-6 % ovalbumin, and exposed to MAbs 15H4 or 20D7 (ascites diluted 1:500 in 3% BSA, 0.6% ovalbumin), washed and bound antibody was detected with horseradish peroxidase-labelled anti-mouse Ig (Kirkegaard) and an enhanced chemiluminescence detection system (Amersham).
Results
We examined the biological half-life of HPV-18 E7 protein in the HPV-transformed cell line HeLa. The concentration of iE7 decayed exponentially with time of exposure to cycloheximide (Fig. 1) . The half-life of iE7 was calculated from three experiments to be 13.0_+ 1"5 rain. We then examined the biological half-life of iE7 in Sf21 cell cultures infected with an E7 recombinant baculovirus, vAcl8E7, which gave relatively low-levd E7 expression. Initial iE7 in these cells was 227 ng/mg protein, exponential decay of E7 con- was 99 min. We also examined the half-life ofiE7 in Sf21 ceils infected with an E7 recombinant baculovirus, vVL18E7, which produced a high yield of E7 protein.
The initial concentration of iE7 was 5735 ng/mg cellular protein, and no measurable loss of iE7 was observed after a 3 h exposure to cycloheximide, giving a calculated half-life for iE7 of > 24 h. We examined the effect on iE7 concentration in HPVtransformed cell lines of exposure of cells to hydrocortisone and other steroid hormones. Exposure of C4-1 or HeLa cells to hydrocortisone was associated with a consistent increase in iE7. Maximal effect was observed for hydrocortisone doses greater than 0.4 ~tM in C4-1 cells, and 1 pM in HeLa cells (Fig. 2) . The total protein was not altered by exposure to hydrocortisone (Fig. 2) . To establish whether there was sufficient hydrocortisone in the FBS used for cell culture to influence the observed results, cell lines were cultured in 2 % or 10,% FBS prior to E7 assay. For HeLa cells, iE7 was 3"5+0"1 ng/mg protein for cells growing in log phase in 10% FBS, 4.0+0.2ng/mg for confluent cells in 10% FBS and Exposure to progesterone, fl-oestradiol or testosterone failed to alter iE7 in HeLa or C4-1 cells (Table 1) . Cortexolone and progesterone inhibit hydrocortisone receptors with partial agonist activity. Cortexolone at 10 pM slightly increased iE7 in C4-1 cells but had no significant effect on the iE7 concentration in HeLa cells (Table 1) . A 10-fold excess of either cortexolone or progesterone showed significant inhibition of the effect ofhydrocortisone on iE7. To determine whether the halflife of iE7 was altered in hydrocortisone-treated HeLa cells, they were treated with hydrocortisone and then exposed to cycloheximide. The half-life of the iE7 protein in hydrocortisone-treated HeLa cells (14.7_+ 1.2 min) was not significantly different from that observed with untreated cells (13.0+0.8 min), and we conclude that hydrocortisone increases cellular E7 levels by increasing E7 transcription or translation, rather than by inhibiting breakdown of this protein.
Our E7-specific MAbs were raised against the MS2 replicase-HPV-18 E7 bacterial fusion protein. Most of our E7-specific MAbs immunoprecipitate similar amounts of the HPV-18 E7 protein from lysates of 35S-labelled HeLa cells. In contrast, one MAb, 15H4, which recognizes a six amino acid linear epitope 33SEEENDaS of E7 ) including one of three potential serine phosphorylation sites in this protein, immunoprecipitates only trace amounts of E7 protein from lysates of [35S]cysteine-labelled HeLa ceils, although recognizing E7 produced in a prokaryotic expression system as effectively as the other E7-specific MAbs. When 35S-labelled HeLa cell lysates were treated with alkaline phosphatase, and then subjected to immunoprecipitation with 15H4, a more intense band with an appropriate size for E7 could be identified (data not shown). We examined further the specificity of 15H4 for HPV-18 E7, using 2D analysis of E7 protein immunoprecipitated from Sf21 cells overexpressing this protein after infection with vVL18E7 (Fig. 3) . E7 protein precipitated by 17C6 was detected by 17C6 as a series of proteins with isoelectric points from 5"5 to 9 (Fig. 3a) , whereas the E7 protein species detected by 15H4 were concentrated at lower pK~ values (Fig. 3 b) . Treatment of cell lysates with alkaline phosphatase prior to immunoprecipitation increased the total amount of E7 protein precipitated by 15H4 (Fig. 3d) , although not the total amount of E7 precipitated by another E7-specific MAb 17C6 which recognizes a conformational epitope (Fig.  3c) . 2D gel analysis of the E7 species precipitated by MAb 17C6 showed a continuous rather than a discrete series of E7 proteins: the single species recognized by 15H4 corresponded to the most acidic of these and was not shifted in electrophoretic mobility by alkaline phosphatase treatment. Taken together, these data suggest that 15C4 recognizes only the E7 species not phosphorylated at Ser 33, and that, in HeLa cells and Sf21 cells overexpressing E7, the vast majority of E7 which is not phosphorylated at this residue is totally dephosphorylated. 2D gel analysis of immunoprecipitated E7 protein by MAb 17C6 shows a marked heterogeneity of E7 species, not reduced by alkaline phosphatase treatment. Presumably the more basic E7 species represent post-translational modifications of E7 other than phosphorylation, and could be precipitated from the cell lysate by MAb 15H4 only after treatment of lysate with alkaline phosphatase, suggesting that these modified E7 species are also routinely phosphorylated. To investigate the phosphorylation at Ser 3~ of E7 expressed in cervical cancer cells, 15H4 was used as a capture antibody for the detection of HPV-18 E7 protein in HeLa cells, using a sandwich ELISA standardized against a constant amount of a MS2 replicase-HPV-18 E7 bacterial fusion protein, which is not phosphorylated. When iE7 was determined in HeLa cell lysates, an 15H4-based ELISA gave a ratio for the reactivity of HeLa cell lysates to that of MS2 replicase-HPV-18 E7 fusion protein which was 10-fold lower than when iE7 was determined using 7El0, or any of the other HPV-18 E7-specific MAbs (Table 2 ). 15H4 therefore reacts with an * MAb used as the capture layer. t Epitopes were defined with a series of overlapping octapeptides spanning the predicted amino acid sequence of HPV-18 E7 . Confl and conf2 are presumed conformational epitopes, defined by the pattern of reactivity of the MAbs in competition assays.
The A492 values were obtained in the sandwich ELISA using 1-5 ng of MS2 replicase-HPV-18 E7 fusion protein as the substrate.
§ Estimated HPV-18 E7 protein concentration in a HeLa cell extract, determined by ELISA using the MAb under test as the capture antibody, expressed as a ratio to the HPV-18 E7 protein concentration in the same extract, estimated by ELISA using MAb 7El0.
0 5 10 Time (min) Fig. 4 . iE7 detected by two MAbs in vVLl8E7-infected Sf21 cells before and after treatment of cell lysate with alkaline phosphatase. Cell lysates were exposed to alkaline phosphatase for 0, 0-1, 2 and 10 min, the reaction was stopped with DTT, and the lysates were tested by capture ELISA for iE7 using MAb 15H4 (O) or 7El0 (I-q). Untreated cell lysates were assayed in parallel (data not shown). Results are the means _ 1 S.D. of four determinations. HPV-18 E7 phosphorylation and steroids 1651 iE7 species present in a concentration 10-fold greater in the MS2 replicase-E7 fusion protein preparation than in HeLa cell lysates: we conclude that Ser33dephospho-E7 represents less than 10% of the total iE7 in these cells.
To confirm the specificity of the 15H4-based capture ELISA for dephospho-E7, we treated lysates of vVL18E7-infected Sf21 cells with alkaline phosphatase, and observed increased reactivity of samples in the ELISA when 15H4 was the capture antibody (Fig. 4) , but no increase when 7El0 was the capture antibody. We used the specificity of 15H4 for Ser3~dephospho-iE7 to estimate the ratio of Ser33dephospho-iE7 to total iE7 protein in two HeLa-fibroblast fusion cell lines of differing tumorigenic potential (CGL-1 and CGL-4): the ratio was similar in both these cell lines to that in the cervical cancer cell lines tested (Table 3) , and also to that in recombinant baculovirus-infected insect cells. We estimated the biological half-life of Ser33dephospho-iE7 after cycloheximide treatment of cells. For HeLa cells, the half-life of Ser33dephospho-iE7 (15min) was the same as that of the total HPV-18 E7 protein. However in cycloheximide-treated vVL18E7-infected Sf21 cells the biological half-life of Ser33dephospho-iE7 protein (90 min) was much shorter than that of total HPV-18 E7 protein (> 24 h), suggesting that SerZ3dephospho-iE7 is an intermediate species, targeted either for conversion to phosphorylated iE7 or for destruction.
Discussion
The short half-life of the HPV-18 E7 protein which we have demonstrated in eukaryotic ceils is consistent with that observed for other regulatory proteins (Luscher & Eisenman, 1988; Ron et aL, 1989; Schubach & Horvath, 1988) , and is in keeping with previously reported observations of the half-life of HPV-16 E7 protein in cervical carcinoma cells (Smotkin & Wettstein, 1987) . The prolonged half-life of iE7 expressed in insect cells was not predicted, as the half-life of mammalian proteins expressed in insect cells is generally similar to that in mammalian cells (Tratner et al., 1990; Grossman et al., 1989) . The longer half-life in insect cells of HPV-18 E7 protein expressed by vVL18E7 compared to vAcl8E7 suggests that, at least in these cells, the E7 half-life is proportional to the initial E7 concentration, and activity of the enzyme(s) required for degradation of HPV-I 8 E7 protein may be limiting the rate of degradation.
The phosphorylation state of many proteins involved in cell cycle regulation is critical to their biological activity. HPV-18 E7 has three potential phosphorylation sites, including Ser 33, which is included in the linear epitope recognized by MAb 15H4 , and the data presented here suggest that the majority of HPV-18 E7 protein in HeLa cells is phosphorylated at Ser 33; Ser 33 in HPV-18 E7 protein corresponds to Ser a~ of the HPV-16 E7 protein. Immunoprecipitation from 32p_ labelled CaSki cells with a rabbit polyclonal antiserum specific for HPV-16 E7 protein has shown that at least a portion of immunoreactive HPV-16 E7 protein is phosphorylated, at at least one serine residue (Smotkin & Wettstein, 1987) , and double substitutions of serine residues 31 and 32 appeared to prevent all phosphorylation of the E7 protein (Barbosa et aL, 1990) ; hence these residues may be the only significant sites of E7 phosphorylation. Our data showed no evidence of differences in E7 protein phosphorylation between two E7-expressing transformed HeLa-fibroblast cell lines of different tumorigenic potential, which appears to exclude regulation of E7 phosphorylation as the mechanism by which the different cell growth properties of these lines Occurs.
Point measurements of iE7 protein concentration in response to external stimuli are unable to differentiate between changes in synthesis, in catabolism or in immunoreactivity of E7 protein in cell lysates. A dexamethasone-induced increase of HPV-16 and -18 mRNA levels in cervical cancer cell lines has been reported (Chan et al., 1989; yon Knebel Doeberitz et al., 1988 . A previous report on HPV-18 E7 protein used a semi-quantitative assay based on a polyclonal antiserum (yon Knebel Doeberitz et al., 1988 ) to show a glucocorticoid-associated increase in immunoreactive HPV-18 E7 protein in C4-1 cell lysates. Our quantitative E7 assay has allowed us to show that the steroid-induced increase in E7 is dose-related, is unrelated to steroid-induced changes in total cellular protein concentrations and occurs over the physiological range of concentrations of hydrocortisone. A postulated mechanism for this increase is via a glucocorticoid response element in the long control regions of both HPV-16 and -18 (Chan et al., 1989; Chong et al., 1990 ). The extremely short half-life of HPV-18 immunoreactive E7 protein suggested that the rate of catabolism of the E7 protein could also be a major determinant of immunoreactive E7 protein levels, but we did not observe a change of the half-life of HPV-18 E7 protein in response to hydrocortisone. Some glucocorticoid response elements are also responsive to progesterone, when progesterone receptors are present in the cell (Stdihle et al., 1990) , whereas oestrogen response elements are related but distinct (Klock et al., 1987) . The levels of progesterone and oestrogen receptors in HeLa and C4-1 cell lysates were determined by radioimmunoassay and no oestrogen or progesterone receptors were detectable in either cell line (data not shown).
Levels of E7 protein appear to influence the proliferative behaviour of HPV-transformed cells (von Knebel Doeberitz et al., 1990) . Progesterone or dexamethasone is a necessary cofactor for the transformation of primary baby rat kidney cells by the early region of HPV-16 or -18 DNA and activated ras, when expression of the HPV early region is not driven by a strong heterologous promoter (Pater et al., 1988 (Pater et al., , 1990 . In vitro, hydrocortisone also increases the frequency of transformation of human keratinocytes by HPV-16 DNA (Schlegel et al., 1988) . As hydrocortisone and progesterone interact with a common glucocorticoid response element, a demonstration of a similar effect of progesterone on immunoreactive E7 protein levels in cervical epithelial cells, which are known to possess a progesterone receptor, could contribute to the higher incidence of invasive cervical cancer in long-term users of the oral contraceptive pill, and the increased detection of HPV DNA in cervical samples from women in the third trimester of pregnancy (Schneider et al., 1987; Rando et al., 1989) .
